Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 575 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People

NCT06821061
Conditions
Influenza, COVID-19 (Coronavirus Disease 2019)
Interventions
Investigational Influenza Vaccine, Investigational COVID-19 Vaccine, Investigational Influenza and COVID-19 Combination Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2, Licensed Influenza Vaccine 3, Licensed COVID-19 Vaccine
Biological · Combination Product
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
31
States / cities
Anaheim, California • Lake Forest, California • Riverside, California + 26 more
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

NCT07287137
Conditions
COVID -19, COVID - 19, COVID 19, Influenza, Respiratory Virus, Respiratory Viruses, Respiratory Virus Infection, Respiratory Virus Infections
Interventions
Pfizer-BioNTech mRNA COVID-19 vaccine, Novavax recombinant protein vaccine
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 79 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Influenza
Interventions
High-Dose trivalent influenza vaccine (Split virion, Inactivated), Standard-dose trivalent influenza vaccine (Split virion, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years to 64 Years
Enrollment
1,180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
20
States / cities
Los Alamitos, California • Fort Myers, Florida • Hollywood, Florida + 16 more
Completed Phase 1Phase 2 Interventional

FluMist in Egg Allergic Patients

NCT01248208
Conditions
Egg Allergy, Eligible for Vaccination Against Influenza
Interventions
FluMist intranasal influenza vaccine, Intramuscular influenza injection ("flu shot")
Biological
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
6 Months and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

NCT01310413
Conditions
Influenza, Influenza Vaccines
Interventions
Influenza A (H5N1) Virus monovalent vaccine, Saline placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 17 Years
Enrollment
842 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
11
States / cities
Paramount, California • Sacramento, California • Newton, Kansas + 8 more
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more
Conditions
Influenza, Virus Diseases
Interventions
H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A, Seasonal trivalent influenza vaccine (TIV), Saline placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 40 Years
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Stockbridge, Georgia • Raleigh, North Carolina • Austin, Texas + 1 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

NCT03312231
Conditions
Avian Influenza, Influenza Immunisation
Interventions
AS03, Inactivated influenza H7N9 vaccine, Phosphate Buffered Saline (PBS) diluent
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 99 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
5
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 2 more
Conditions
Influenza
Interventions
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Mesa, Arizona
Completed No phase listed Observational Accepts healthy volunteers

BLYS and IFN in SLE

NCT00611611
Conditions
Systemic Lupus Erythematosus
Interventions
fluzone, pneumovax
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

NCT03028974
Conditions
Influenza
Interventions
Fluzone®, FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 49 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Stanford, California
Conditions
Diabetes, Foot Ulcer
Interventions
Tailored Intervention (TI), Current Practice (CP)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Influenza, Human
Interventions
D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03, D-SUIV cH8/1N1+AS01, D-SUIV cH5/1N1+AS01, D-SUIV cH11/1N1+AS01, D-SUIV cH8/1N1, D-SUIV cH5/1N1, D-SUIV cH11/1N1, Placebo, Fluarix Quadrivalent
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 39 Years
Enrollment
470 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
5
States / cities
South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more
Conditions
Influenza, Vaccine
Interventions
cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS)
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 39 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Durham, North Carolina • Cincinnati, Ohio
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
23-PPV, 13-PCV Booster, Influenza Vaccine, KLH, OCR, TT Vaccine
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
20
States / cities
Cullman, Alabama • Tucson, Arizona • Fullerton, California + 17 more
Conditions
HIV Infections, H1N1 Influenza Virus
Interventions
Influenza A (H1N1) monovalent vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
29
States / cities
Alhambra, California • La Jolla, California • Long Beach, California + 22 more
Conditions
Immunizations, Vaccination, Influenza, School Health
Interventions
School based flu vaccine: Low intensity, School based flu vaccine: High intensity
Behavioral
Lead sponsor
Monroe County Department of Public Health
Other
Eligibility
4 Years to 13 Years
Enrollment
25,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, New York
Conditions
Influenza, Healthy Volunteers
Interventions
Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza Vaccine High Dose
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years and older
Enrollment
1,162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 18 more
Conditions
Influenza A Virus, H5N1 Subtype
Interventions
VN, IN, dk/BANG, gf/WA, bhg/QL, AS03 adjuvant, MF59 adjuvant
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 49 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
San Diego, California • Peoria, Illinois • Lenexa, Kansas + 3 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

H5N1 Priming and Boosting Strategies

NCT00703053
Conditions
Influenza
Interventions
A/Vietnam/1203/04, A/Indonesia/05/05
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
5
States / cities
Decatur, Georgia • Rochester, Minnesota • St Louis, Missouri + 1 more
Terminated Phase 4 Interventional Accepts healthy volunteers

Th1 Response to Influenza: Aging and Vaccine Efficacy

NCT00396305
Conditions
Influenza
Interventions
Placebo, Trivalent Inactivated Influenza
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Norfolk, Virginia
Conditions
Influenza, Virus Diseases
Interventions
H6N1 Teal HK 97/AA ca recombinant vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Healthy or Stable Underlying Chronic Medical Condition
Interventions
Q/LAIV-BFS (MEDI8662), FluMist/B/Yamagata, FluMist/B/Victoria
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
18
States / cities
Mobile, Alabama • Sacramento, California • San Diego, California + 15 more